Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
Cephalon, Inc. (Nasdaq: CEPH) today announced that Risk Evaluation and Mitigation Strategies (REMS) for its...
FDA approves Herceptin for HER2-positive metastatic stomach cancer
Roche announced the U.S. Food and Drug Administration (FDA) has approved Herceptin (trastuzumab) in combination...
Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON(TM)
Amylin Pharmaceuticals, Inc. Eli Lilly and Company and Alkermes, Inc.announced that the U.S. Food and...
Endress+Hauser Announces Collaboration with SAP as a Core Partner of the Future Factory Initiative...
SAP Research is the global technology research unit of SAP. The group significantly contributes...
NeurogesX to Pursue Expanded U.S Label for Qutenza(R) 8% Patch in HIV-Associated Neuropathy
NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today...
AVEVA to Exhibit at Drug Delivery Partnerships 2011
Aveva Drug Delivery Systems is pleased to announce that it will exhibit at Drug...
Italvacuum to Attend India CHEM 2010
We are pleased to announce that Italvacuum is participating India CHEM 2010, the largest...
APR and Labtec enter into exclusive License Agreement with Ferrer International
APR and its development partner Labtec have entered into an exclusive licensing agreement with the...
Genzyme’s Alemtuzumab Shows Sustained Reduction in Relapses and Disability in Five-Year Review of MS...
Genzyme Corporation reported five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial....
Weight Watchers and Merck Collaborate to Help Physicians Fight Obesity Through Lifestyle Management Approach
NEW YORK, NY and Whitehouse Station, NJ (October 13, 2010) – Weight Watchers International, Inc.,...
